Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD

IntroductionChronic obstructive pulmonary disease (COPD) is a disease with severe therapeutic obstacles and high worldwide death rate. COPD progresses predominantly through inflammatory response followed by fibrotic destruction. Quercetin (Que), recognized for its anti-inflammatory effects, presents...

Full description

Saved in:
Bibliographic Details
Main Authors: Changfeng Yin, Yushan Tian, An Yan, Hongjuan Wang, Fengjun Lu, Xianmei Li, Xiao Li, Shulei Han, Ruijuan Miao, Huan Chen, Di Li, Hongwei Hou, Qingyuan Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1503283/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846119291601027072
author Changfeng Yin
Changfeng Yin
Changfeng Yin
Yushan Tian
Yushan Tian
Yushan Tian
An Yan
Hongjuan Wang
Hongjuan Wang
Hongjuan Wang
Fengjun Lu
Fengjun Lu
Xianmei Li
Xianmei Li
Xiao Li
Xiao Li
Xiao Li
Shulei Han
Shulei Han
Shulei Han
Ruijuan Miao
Ruijuan Miao
Huan Chen
Huan Chen
Huan Chen
Di Li
Hongwei Hou
Hongwei Hou
Hongwei Hou
Qingyuan Hu
Qingyuan Hu
Qingyuan Hu
author_facet Changfeng Yin
Changfeng Yin
Changfeng Yin
Yushan Tian
Yushan Tian
Yushan Tian
An Yan
Hongjuan Wang
Hongjuan Wang
Hongjuan Wang
Fengjun Lu
Fengjun Lu
Xianmei Li
Xianmei Li
Xiao Li
Xiao Li
Xiao Li
Shulei Han
Shulei Han
Shulei Han
Ruijuan Miao
Ruijuan Miao
Huan Chen
Huan Chen
Huan Chen
Di Li
Hongwei Hou
Hongwei Hou
Hongwei Hou
Qingyuan Hu
Qingyuan Hu
Qingyuan Hu
author_sort Changfeng Yin
collection DOAJ
description IntroductionChronic obstructive pulmonary disease (COPD) is a disease with severe therapeutic obstacles and high worldwide death rate. COPD progresses predominantly through inflammatory response followed by fibrotic destruction. Quercetin (Que), recognized for its anti-inflammatory effects, presents significant promise as a therapeutic candidate for COPD therapy. However, poor water solubility and low bioavailability of Que hinder its further clinical application. Liposomes are renowned for their unique structure and function, which provided an efficient approach for the delivery of Que in various drug delivery systems. This study was aim to prepare a novel Que liposome (Que-lipo) and administrated via intratracheal (i.t.) with cigarette smoke induced COPD mice. The underlying therapeutic mechanisms against lung damage of Que-lipo were explored.MethodsQue-lipo were prepared based on thin film dispersion method and administrated via intratracheal administration. The cigarette smoke induced COPD mice were established and a comprehensive approach was employed to explore the inflammation, pulmonary function and histopathology of lung after i.t. administration of Que-lipo, including enzyme-linked immunosorbent assay, histopathology and immunohistochemistry, reverse transcription-quantitative polymerase chain reaction.Results and discussionQue-lipo not only improved the solubility and biocompatibility of Que but also demonstrated effective cellular uptake in vitro. The inflammation, pulmonary function and pathological condition of lung were improved after i.t. administration of Que-lipo. Que-lipo also regulated the expression of key apoptosis-associated proteins such as Bcl-2 and caspase-3/7, leading to significant inhibition of apoptotic activity in COPD. Furthermore, Que-lipo markedly enhanced its ability to alleviate lung inflammation and fibrosis symptoms by modulating inflammation-related factors and fibrosis signaling molecules. The potential mechanisms of Que-lipo in treating COPD were elucidated, including the suppression of the NLRP3/IL-1β inflammasome pathway and the TGF-β1-related fibrosis signaling pathway.
format Article
id doaj-art-e10e5e94ac8b4ce2bfff92dc2cc7f76c
institution Kabale University
issn 1663-9812
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-e10e5e94ac8b4ce2bfff92dc2cc7f76c2024-12-17T06:23:09ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.15032831503283Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPDChangfeng Yin0Changfeng Yin1Changfeng Yin2Yushan Tian3Yushan Tian4Yushan Tian5An Yan6Hongjuan Wang7Hongjuan Wang8Hongjuan Wang9Fengjun Lu10Fengjun Lu11Xianmei Li12Xianmei Li13Xiao Li14Xiao Li15Xiao Li16Shulei Han17Shulei Han18Shulei Han19Ruijuan Miao20Ruijuan Miao21Huan Chen22Huan Chen23Huan Chen24Di Li25Hongwei Hou26Hongwei Hou27Hongwei Hou28Qingyuan Hu29Qingyuan Hu30Qingyuan Hu31China National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaChina National Tobacco Quality Supervision & Test Center, Zhengzhou, ChinaBeijing Life Science Academy, Beijing, ChinaKey Laboratory of Tobacco Biological Effects, Zhengzhou, ChinaIntroductionChronic obstructive pulmonary disease (COPD) is a disease with severe therapeutic obstacles and high worldwide death rate. COPD progresses predominantly through inflammatory response followed by fibrotic destruction. Quercetin (Que), recognized for its anti-inflammatory effects, presents significant promise as a therapeutic candidate for COPD therapy. However, poor water solubility and low bioavailability of Que hinder its further clinical application. Liposomes are renowned for their unique structure and function, which provided an efficient approach for the delivery of Que in various drug delivery systems. This study was aim to prepare a novel Que liposome (Que-lipo) and administrated via intratracheal (i.t.) with cigarette smoke induced COPD mice. The underlying therapeutic mechanisms against lung damage of Que-lipo were explored.MethodsQue-lipo were prepared based on thin film dispersion method and administrated via intratracheal administration. The cigarette smoke induced COPD mice were established and a comprehensive approach was employed to explore the inflammation, pulmonary function and histopathology of lung after i.t. administration of Que-lipo, including enzyme-linked immunosorbent assay, histopathology and immunohistochemistry, reverse transcription-quantitative polymerase chain reaction.Results and discussionQue-lipo not only improved the solubility and biocompatibility of Que but also demonstrated effective cellular uptake in vitro. The inflammation, pulmonary function and pathological condition of lung were improved after i.t. administration of Que-lipo. Que-lipo also regulated the expression of key apoptosis-associated proteins such as Bcl-2 and caspase-3/7, leading to significant inhibition of apoptotic activity in COPD. Furthermore, Que-lipo markedly enhanced its ability to alleviate lung inflammation and fibrosis symptoms by modulating inflammation-related factors and fibrosis signaling molecules. The potential mechanisms of Que-lipo in treating COPD were elucidated, including the suppression of the NLRP3/IL-1β inflammasome pathway and the TGF-β1-related fibrosis signaling pathway.https://www.frontiersin.org/articles/10.3389/fphar.2024.1503283/fullchronic obstructive pulmonary diseaseinflammationfibrosisquercetinliposomes
spellingShingle Changfeng Yin
Changfeng Yin
Changfeng Yin
Yushan Tian
Yushan Tian
Yushan Tian
An Yan
Hongjuan Wang
Hongjuan Wang
Hongjuan Wang
Fengjun Lu
Fengjun Lu
Xianmei Li
Xianmei Li
Xiao Li
Xiao Li
Xiao Li
Shulei Han
Shulei Han
Shulei Han
Ruijuan Miao
Ruijuan Miao
Huan Chen
Huan Chen
Huan Chen
Di Li
Hongwei Hou
Hongwei Hou
Hongwei Hou
Qingyuan Hu
Qingyuan Hu
Qingyuan Hu
Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
Frontiers in Pharmacology
chronic obstructive pulmonary disease
inflammation
fibrosis
quercetin
liposomes
title Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
title_full Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
title_fullStr Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
title_full_unstemmed Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
title_short Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
title_sort mitigating inflammation and fibrosis the therapeutic potential of quercetin liposomes in copd
topic chronic obstructive pulmonary disease
inflammation
fibrosis
quercetin
liposomes
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1503283/full
work_keys_str_mv AT changfengyin mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT changfengyin mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT changfengyin mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT yushantian mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT yushantian mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT yushantian mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT anyan mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT hongjuanwang mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT hongjuanwang mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT hongjuanwang mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT fengjunlu mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT fengjunlu mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT xianmeili mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT xianmeili mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT xiaoli mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT xiaoli mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT xiaoli mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT shuleihan mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT shuleihan mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT shuleihan mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT ruijuanmiao mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT ruijuanmiao mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT huanchen mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT huanchen mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT huanchen mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT dili mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT hongweihou mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT hongweihou mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT hongweihou mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT qingyuanhu mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT qingyuanhu mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd
AT qingyuanhu mitigatinginflammationandfibrosisthetherapeuticpotentialofquercetinliposomesincopd